secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2026-05-19T21:17:03+00:00
Accession:  0001213900-26-059127
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart files preliminary proxy; urges support for board nominees amid dissident challenge
--------------------------------------------------------------------------------

- Annual meeting set for July 16, 2026; preliminary proxy filed with SEC.
- Dissident shareholder group nominated three candidates; company says they lack relevant biotech experience.
- Cash resources ~$61M as of Q1 2026; funded runway into Q2 2027.
- BARDA COVID-19 Phase 2b trial restored after stop-work order; main cohort primary readout expected early 2027.
- CEO holds over 2.5M shares and has never sold a share; board added Dr. James Breitmeyer in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000121390026059127/0001213900-26-059127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000121390026059127/ea0291449-8k_vaxart.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-059127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer